TRIKAFTA (COPACKAGED) Drug Patent Profile

When do Trikafta (copackaged) patents expire, and what generic alternatives are available?

Trikafta (copackaged) is a drug marketed by Vertex Pharms Inc and is included in two NDAs. There are thirty-five patents protecting this drug.

This drug has five hundred and nineteen patent family members in forty-eight countries.

The generic ingredient in TRIKAFTA (COPACKAGED) is elexacaftor, ivacaftor, tezacaftor; ivacaftor. One supplier is listed for this compound. Additional details are available on the elexacaftor, ivacaftor, tezacaftor; ivacaftor profile page.

DrugPatentWatch^® Generic Entry Outlook for Trikafta (copackaged)

Trikafta (copackaged) was eligible for patent challenges on October 21, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 8, 2037. This may change due to patent challenges or generic licensing.

There have been six patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TRIKAFTA (COPACKAGED)

International Patents:	519
US Patents:	35
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRIKAFTA (COPACKAGED)

US Patents and Regulatory Information for TRIKAFTA (COPACKAGED)

TRIKAFTA (COPACKAGED) is protected by eighty-nine US patents and nine FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 11,453,655.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	GRANULES;ORAL	217660-002	Apr 26, 2023		RX	Yes	Yes	8,410,274		Y
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	TABLET;ORAL	212273-001	Oct 21, 2019		RX	Yes	Yes	9,670,163		Y
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	TABLET;ORAL	212273-002	Jun 8, 2021		RX	Yes	No	11,453,655		Y	Y

International Patents for TRIKAFTA (COPACKAGED)

When does loss-of-exclusivity occur for TRIKAFTA (COPACKAGED)?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Georgia, Republic of

Hungary

Israel

Japan

Jordan

Lithuania

Mexico

Moldova, Republic of

Morocco

New Zealand

Peru

Portugal

San Marino

Saudi Arabia

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRIKAFTA (COPACKAGED) around the world.

Country	Patent Number	Title	Estimated Expiration
Slovenia	3091011
World Intellectual Property Organization (WIPO)	2010019239
Hong Kong	1161140

Supplementary Protection Certificates for TRIKAFTA (COPACKAGED)

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1773816	35/2015	Austria		PRODUCT NAME: N-(5-HYDROXY-2,4DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLIN-3-CARBOXAMID ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/12/782/001, EU/1/12/782/002 (MITTEILUNG) 20120725
1773816	1590036-8	Sweden		PRODUCT NAME: N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3- CARBOXAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/12/782/001, 2012-07-25; DEN 2025-05-21 MEDDELADE PRV BESLUT OM RAETTAD SKYDDSTID FOER FOELJANDE TILLAEGGSSKYDD: 1590036-8,1690018-5, 1490016-1
2826776	21C1018	France		PRODUCT NAME: TEZACAFTOR ET IVACAFTOR, SOUS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; REGISTRATION NO/DATE: EU/1/18/1306 20181106

Investment Scenario and Fundamentals Analysis for TRIKAFTA (COPACKAGED)

Last updated: February 19, 2026

What Is TRIKAFTA and Its Market Position?

TRIKAFTA (tezacaftor/ivacaftor/elexacaftor), marketed as a combination therapy for cystic fibrosis (CF), is a co-packaged drug developed by Vertex Pharmaceuticals. Approved by the FDA in October 2019, it addresses the underlying genetic defect by targeting CFTR proteins. TRIKAFTA is positioned as a first-line treatment, replacing earlier therapies like Kalydeco and Orkambi in many patients.

The drug markets primarily in North America, Europe, and select Asia-Pacific regions, with over 8,000 annual prescriptions in the U.S. alone.

Investment Considerations

• Market Penetration and Growth: The global CF therapeutics market was valued at approximately USD 4.5 billion in 2021, with expected CAGR of 4% through 2028. TRIKAFTA accounts for roughly 45% of this market segment, primarily due to its expanded indication scope.

• Patent and Regulatory Lifecycle: Patent protection extends to 2035, with regulatory exclusivity in various jurisdictions until 2038. The drug has completed multiple phase 3 trials showing significant improvements in lung function.

• Pricing and Revenue: In the U.S., list price exceeds USD 18,000 per month. Reimbursement is generally favorable, with high insurance coverage among the target demographic. Vertex's 2022 revenue from TRIKAFTA/ETI (elexacaftor/tezacaftor/ivacaftor) was USD 6.2 billion, contributing over 60% of total sales.

• Pipeline and Line Extensions: Vertex plans to expand indications to younger ages (as young as 6 months), potentially expanding total market size. A phase 3 trial for CF pediatric patients aged 6-11 completed enrollment in July 2022.

• Manufacturing Risks and Supply Chain: As an advanced biologic, manufacturing complexity could impact supply stability. Vertex maintains multiple manufacturing sites in North America and Europe, reducing geopolitical risks.

Financial Fundamentals

Metric	2022 Values	Notes
Total Revenue	USD 10.2 billion	Up 12% YoY
R&D Expenses	USD 2.1 billion	Represents 20.6% of total revenue
Operating Margin	50%	Reflects high gross margins and efficient commercialization
Net Profit Margin	45%	Due to high drug pricing and economies of scale
Cash & Equivalents	USD 4.5 billion	Sufficient for ongoing pipeline development
Long-term Debt	USD 4.2 billion	Slightly high but manageable, with strong cash flow

Revenue Breakdown

TRIKAFTA/ETI contributed significantly, with North America generating around 65% of sales, Europe 25%, and the rest emerging markets. International expansion and approval in Japan (2022) are poised to increase revenues.

Competitive Landscape

Competitors	Key Drugs (if available)	Market Share	Notes
AbbVie	Humira (biosimilars for CF)	Small	No direct CF competition
Moderna, BioNTech	mRNA-based therapies for other genetic diseases	Emerging	Not directly competing but potential future threat
Vertex Pharmaceuticals	Kalydeco (ivacaftor), Orkambi (lumacaftor/ivacaftor)	Substantial	TRIKAFTA replacing older combinations in market

Vertex's strategic focus on expanding indications and pediatric use supports future revenue growth.

Risks and Challenges

• Pricing and Reimbursement: Pricing pressure may emerge due to cost containment measures in healthcare systems globally.
• Patent Challenges: Patent litigations or challenges could threaten exclusivity in the late 2020s.
• Pipeline Risks: The success of pipeline candidates like next-generation CFTR modulators is uncertain.
• Manufacturing: Complexity and capacity constraints in biologic production could affect supply.

Valuation and Investment Potential

Valuation models using DCF approaches suggest a current enterprise value of approximately USD 70 billion, assuming a weighted average cost of capital (WACC) of 8%, a terminal growth rate of 2%, and revenue projections consistent with current trends.

Sensitivity analyses show valuation fluctuates notably with changes in market penetration rates, pricing strategies, and pipeline success probabilities.

Key Takeaways

• TRIKAFTA’s dominant position in the CF market and Vertex’s expanding indications underpin robust revenue streams.
• High margins and strong cash flow support aggressive pipeline development and potential for near-term growth acceleration.
• Patent life and regulatory exclusivity provide protection until 2038, with potential extensions.
• Risks include pricing pressures, patent challenges, and manufacturing capacity constraints.

FAQs

1. What is the primary indication for TRIKAFTA?
It is indicated for cystic fibrosis patients with at least one F508del mutation.

2. When are additional indications expected?
Regulatory submissions for pediatric populations and earlier age groups are ongoing, with decisions anticipated through 2024.

3. How does TRIKAFTA compare to earlier CF therapies?
It provides higher efficacy in lung function improvement and addresses a broader genetic patient population.

4. What are the main growth drivers?
Expansion into pediatric markets, new geographic approvals, and pipeline enhancements.

5. What risks could threaten TRIKAFTA’s market share?
Pricing pressures, patent disputes, or successful pipeline competitors could erode monopolistic advantage.

---

References

[1] Vertex Pharmaceuticals. (2022). Annual Report 2022.
[2] Pharmaceutical Commerce. (2022). CF Therapeutics Market Overview.
[3] MarketWatch. (2023). Global cystic fibrosis drug market forecasts.
[4] FDA. (2019). Approval notification for TRIKAFTA.